Breast Cancer in Young Women: Reading the Red Flags Beyond Age

A 35-year-old software engineer in Bangalore came to Dr. Niti Raizada's clinic for an unrelated reason. She was married, had regular periods, and had been seeing fertility specialists to understand why she had not been able to conceive. During that workup she mentioned a painless lump in her right breast that had been growing for two months.

The history that changed the working diagnosis

In a woman in her twenties, breast cancer is rarely the first differential. But two details in this patient's history moved it to the top of the list. Her mother had been diagnosed with breast cancer at 45, and her aunt with ovarian cancer at 47. Both were premenopausal at diagnosis. Family history at a young age, across both breast and ovarian cancer, is itself a clinical signal, independent of any examination finding.

On clinical examination, the mass measured roughly 4 by 3 centimetres, hard and irregular, sitting in the upper outer quadrant of the right breast, the most common site for breast malignancy. A right axillary lymph node measuring 1.5 centimetres was also palpable. Combined with the family history, this was no longer a routine finding in a young woman: it was a hard, irregular mass with nodal involvement and a first-degree relative diagnosed young.

The triple assessment, and why the biopsy choice matters

Dr. Raizada's protocol for any suspicious breast finding is a triple assessment: clinical examination, imaging, and tissue. Imaging depends on age. Women 40 and above are offered a mammogram; under 40, an ultrasound is preferred, though a mammogram can still be added if suspicion is high, as it was here. If either shows a suspicious lesion, the next step is a tru-cut biopsy, not a fine needle aspiration. A tru-cut sample provides tissue architecture, which a fine needle sample cannot, and that architecture is what a pathologist needs to grade the tumour and subtype it correctly.

This patient's ultrasound showed a BI-RADS 4 lesion. A mammogram, added because of the strength of the clinical suspicion, showed a spiculated mass with microcalcification, a pattern strongly associated with malignancy. The tru-cut biopsy confirmed invasive ductal carcinoma, Grade 2.

Triple-negative disease: aggressive, but not a reason to rush to surgery

Every breast biopsy at Dr. Raizada's centre is followed by receptor testing: oestrogen receptor, progesterone receptor, and HER2. In this patient, all three came back negative, making this triple-negative breast cancer, a subtype seen disproportionately in young women and considered the most aggressive form of the disease. A young woman with triple-negative breast cancer is treated as having an aggressive, systemic disease from the outset, which changes the sequence of treatment.

Counterintuitively, the first step was not surgery. The patient underwent a PET-CT scan, which in India is often preferred over separate CT chest, CT abdomen and pelvis, and bone scans, because PET-CT facilities are widely available in most cities and typically return results within a few hours. Before the scan, kidney function is checked to confirm the patient can safely receive iodinated contrast. The PET-CT confirmed this was non-metastatic disease, and because she was young with a curable cancer, fertility preservation counselling was built into the treatment plan before chemotherapy began: for a married woman this generally means embryo cryopreservation, while an unmarried woman may be offered oocyte harvesting or ovarian tissue cryopreservation.

Because the tumour was triple-negative, she was offered neoadjuvant chemotherapy first, followed by surgery. Given the strength of her family history, genetic testing, a simple blood draw, was also offered. It identified a significant mutation that raises her risk not only of a second, bilateral breast cancer, but of cancers at other sites, including the ovaries and pancreas. In male relatives who carry the same mutation, it raises the risk of prostate cancer, which is why genetic counselling in a case like this extends to the whole family, not just the patient.

The clinical takeaway

Age under 40 does not rule out breast cancer, and a hard, irregular mass with a strong family history should trigger the same triple assessment regardless of the patient's age or reason for presenting. The next article in this series covers the screening schedule Dr. Raizada recommends, by age, for every woman, not only those with a known risk factor.